This content was originally shared by a registered user, but access has expired. Create a free account to gain permanent access to all PracticeUpdate content.
Already Have An Account? Log in Now
Efficacy of High- and Low-Dose Preoperative Ipilimumab Plus Nivolumab in Patients With Stage III Urothelial Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial
Nat. Med. 2023 Feb 02;[EPub Ahead of Print], J van Dorp, C Pipinikas, BBM Suelmann, N Mehra, N van Dijk, G Marsico, ML van Montfoort, S Hackinger, LM Braaf, T Amarante, C van Steenis, K McLay, A Daletzakis, D van den Broek, MW van de Kamp, K Hendricksen, JM de Feijter, TN Boellaard, RP Meijer, TG van der Heijden, N Rosenfeld, BWG van Rhijn, G Jones, MS van der HeijdenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.